Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension - Takeaways - MDSpire

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • By

  • WenXia Li

  • RuRan Li

  • ShanShan Li

  • Zhen Li

  • JingSu Ma

  • Fei Wu

  • ChaoQin Chen

  • May 11, 2026

  • 0 min

Share

  • 1

    The study evaluated the effects of dapagliflozin and linagliptin combination therapy on glycemic control in patients with Type 2 diabetes and hypertension.

  • 2

    Combination therapy significantly improved Time in Range (TIR) to 94.86%, compared to ~80% in monotherapies and 81.44% in the control group.

  • 3

    Participants receiving combination therapy showed greater reductions in HbA1c, fasting glucose, blood pressure, and liver enzymes compared to monotherapy.

  • 4

    The combination treatment also resulted in improved renal function, with estimated glomerular filtration rate (eGFR) increasing to 122.41 mL/min/1.73m².

  • 5

    Dapagliflozin and linagliptin combination therapy offers enhanced glycemic stability and organ protection for managing Type 2 diabetes with hypertension.

Original Source(s)

Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension

  • by WenXia Li, RuRan Li, ShanShan Li, Zhen Li, JingSu Ma, Fei Wu, ChaoQin Chen

  • May 11, 2026

Related Content

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

High-fat diet-induced obesity impairs endothelium-dependent relaxation in rabbits: association with MLCK upregulation and partial ex vivo improvement by ML-7

Global Trends and Research Topics in Gastric Bypass Clinical Trials: A Bibliometric Analysis and Latent Dirichlet Allocation (LDA) Study